Literature DB >> 21493664

Once daily insulin detemir in cystic fibrosis with insulin deficiency.

Shihab Hameed1, John R Morton, Penny I Field, Yvonne Belessis, Terence Yoong, Tamarah Katz, Helen J Woodhead, Jan L Walker, Kristen A Neville, Thomas A Campbell, Adam Jaffé, Charles F Verge.   

Abstract

The aim of this study was to determine if once daily insulin detemir reverses decline in weight and lung function in patients with cystic fibrosis (CF). 12 patients with early insulin deficiency and six with CF related diabetes (aged 7.2-18.1 years) were treated for a median of 0.8 years. Changes in weight and lung function following treatment were compared to pretreatment changes. Before treatment, the change in weight SD score (ΔWtSDS), percentage of predicted forced expiratory volume in 1 s (Δ%FEV(1)) and percentage of predicted forced vital capacity (Δ%FVC) declined in the whole study population (-0.45±0.38, -7.9±12.8%, -5.8±14.3%) and in the subgroup with early insulin deficiency (-0.41±0.43, -9.8±9.3%, -6.8±10.3%). Following treatment with insulin ΔWtSDS, Δ%FEV(1) and Δ%FVC significantly improved in the whole study population (+0.18±0.29 SDS, p=0.0001; +3.7±10.6%, p=0.007; +5.2±12.7%, p=0.013) and in patients with early insulin deficiency (+0.22±0.31 SDS, p=0.003; +5.3±11.5%, p=0.004; +5.8±13.4%, p=0.024). Randomised controlled trials are now needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21493664     DOI: 10.1136/adc.2010.204636

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  6 in total

1.  The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults With Cystic Fibrosis.

Authors:  Christine L Chan; Laura Pyle; Tim Vigers; Philip S Zeitler; Kristen J Nadeau
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 6.134

2.  Diabetes and Prediabetes in Children With Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED).

Authors:  Enza Mozzillo; Roberto Franceschi; Claudia Piona; Stefano Passanisi; Alberto Casertano; Dorina Pjetraj; Giulio Maltoni; Valeria Calcaterra; Vittoria Cauvin; Valentino Cherubini; Giuseppe D'Annunzio; Adriana Franzese; Anna Paola Frongia; Fortunato Lombardo; Donatella Lo Presti; Maria Cristina Matteoli; Elvira Piccinno; Barbara Predieri; Ivana Rabbone; Andrea Enzo Scaramuzza; Sonia Toni; Stefano Zucchini; Claudio Maffeis; Riccardo Schiaffini
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-29       Impact factor: 5.555

Review 3.  Maintenance of nutritional status in patients with cystic fibrosis: new and emerging therapies.

Authors:  Daina Kalnins; Michael Wilschanski
Journal:  Drug Des Devel Ther       Date:  2012-06-20       Impact factor: 4.162

Review 4.  Diabetic lung disease: fact or fiction?

Authors:  Saeed Kolahian; Veronika Leiss; Bernd Nürnberg
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

5.  Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine.

Authors:  Francesco Maria Rosanio; Enza Mozzillo; Chiara Cimbalo; Alberto Casertano; Angela Sepe; Valeria Raia; Adriana Franzese; Antonella Tosco
Journal:  Ital J Pediatr       Date:  2021-06-02       Impact factor: 2.638

Review 6.  Insulin therapy in patients with cystic fibrosis in the pre-diabetes stage: a systematic review.

Authors:  Mariana Zorrón Mei Hsia Pu; Flávia Corrêa Christensen-Adad; Aline Cristina Gonçalves; Walter José Minicucci; José Dirceu Ribeiro; Antonio Fernando Ribeiro
Journal:  Rev Paul Pediatr       Date:  2016-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.